143 related articles for article (PubMed ID: 37291277)
1. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.
Darabi S; Xiu J; Samec T; Kesari S; Carrillo J; Aulakh S; Walsh KM; Sengupta S; Sumrall A; Spetzler D; Glantz M; Demeure MJ
Med Oncol; 2023 Jun; 40(7):197. PubMed ID: 37291277
[TBL] [Abstract][Full Text] [Related]
2. CIC reduces xCT/SLC7A11 expression and glutamate release in glioma.
Park JW; Kilic O; Deo M; Jimenez-Cowell K; Demirdizen E; Kim H; Turcan Ş
Acta Neuropathol Commun; 2023 Jan; 11(1):13. PubMed ID: 36647117
[TBL] [Abstract][Full Text] [Related]
3. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.
Gleize V; Alentorn A; Connen de Kérillis L; Labussière M; Nadaradjane AA; Mundwiller E; Ottolenghi C; Mangesius S; Rahimian A; Ducray F; ; Mokhtari K; Villa C; Sanson M
Ann Neurol; 2015 Sep; 78(3):355-74. PubMed ID: 26017892
[TBL] [Abstract][Full Text] [Related]
4. Integrative multi-omic analysis reveals neurodevelopmental gene dysregulation in CIC-knockout and IDH1-mutant cells.
Lee SD; Song J; LeBlanc VG; Marra MA
J Pathol; 2022 Mar; 256(3):297-309. PubMed ID: 34767259
[TBL] [Abstract][Full Text] [Related]
5. Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade.
LeBlanc VG; Firme M; Song J; Chan SY; Lee MH; Yip S; Chittaranjan S; Marra MA
J Pathol; 2017 Jun; 242(2):206-220. PubMed ID: 28295365
[TBL] [Abstract][Full Text] [Related]
6. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma.
Simón-Carrasco L; Graña O; Salmón M; Jacob HKC; Gutierrez A; Jiménez G; Drosten M; Barbacid M
Genes Dev; 2017 Jul; 31(14):1456-1468. PubMed ID: 28827401
[TBL] [Abstract][Full Text] [Related]
9. A double-edged sword: The world according to Capicua in cancer.
Tanaka M; Yoshimoto T; Nakamura T
Cancer Sci; 2017 Dec; 108(12):2319-2325. PubMed ID: 28985030
[TBL] [Abstract][Full Text] [Related]
10. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
[TBL] [Abstract][Full Text] [Related]
11. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
[TBL] [Abstract][Full Text] [Related]
12. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
13. Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.
Eisenreich S; Abou-El-Ardat K; Szafranski K; Campos Valenzuela JA; Rump A; Nigro JM; Bjerkvig R; Gerlach EM; Hackmann K; Schröck E; Krex D; Kaderali L; Schackert G; Platzer M; Klink B
PLoS One; 2013; 8(9):e76623. PubMed ID: 24086756
[TBL] [Abstract][Full Text] [Related]
14. Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
Björkblom B; Wibom C; Eriksson M; Bergenheim AT; Sjöberg RL; Jonsson P; Brännström T; Antti H; Sandström M; Melin B
Neuro Oncol; 2022 Sep; 24(9):1454-1468. PubMed ID: 35157758
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.
Weissmann S; Cloos PA; Sidoli S; Jensen ON; Pollard S; Helin K
Cancer Res; 2018 Aug; 78(15):4114-4125. PubMed ID: 29844126
[TBL] [Abstract][Full Text] [Related]
16. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.
Chittaranjan S; Chan S; Yang C; Yang KC; Chen V; Moradian A; Firme M; Song J; Go NE; Blough MD; Chan JA; Cairncross JG; Gorski SM; Morin GB; Yip S; Marra MA
Oncotarget; 2014 Sep; 5(17):7960-79. PubMed ID: 25277207
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
18.
Yang R; Chen LH; Hansen LJ; Carpenter AB; Moure CJ; Liu H; Pirozzi CJ; Diplas BH; Waitkus MS; Greer PK; Zhu H; McLendon RE; Bigner DD; He Y; Yan H
Cancer Res; 2017 Nov; 77(22):6097-6108. PubMed ID: 28939681
[TBL] [Abstract][Full Text] [Related]
19. Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
Bettegowda C; Agrawal N; Jiao Y; Sausen M; Wood LD; Hruban RH; Rodriguez FJ; Cahill DP; McLendon R; Riggins G; Velculescu VE; Oba-Shinjo SM; Marie SK; Vogelstein B; Bigner D; Yan H; Papadopoulos N; Kinzler KW
Science; 2011 Sep; 333(6048):1453-5. PubMed ID: 21817013
[TBL] [Abstract][Full Text] [Related]
20. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
Wong D; Lee TH; Lum A; Tao VL; Yip S
Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
